Ranjana Advani, Other is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Palo Alto, CA
She has not yet shared a personalized biography with Doctor.com.
University | Degree | Focus | Graduated |
---|---|---|---|
Butler University in Indianapolis | Medical Degree | Not Specified | |
Bombay University, K.J. Somaiya Medical College And Research Centre | Medical Degree | 1982 | |
Grant Government Medical College | Medical Degree | 1982 |
Institution | Focus | Year |
---|---|---|
Internship - Santa Clara Valley Medical Center | 1987 | |
Residency - Stanford University School of Medicine | 1990 | |
Residency - Stanford University Program | Not Specified | |
Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 1996 |
Certification | Cert. Body | Year |
---|---|---|
Sub-Specialty: Medical Oncology | Internal Medicine | 1995 |
Publication | Publisher | Title | Published |
---|---|---|---|
Other Publication | Leukemia & lymphoma | Bevacizumab and cyclosphosphamide, doxorubicin | 2014 |
Other Publication | Jourl of clinical oncology | Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte | 2014 |
Other Publication | Blood | Phase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma | 2014 |
Other Publication | NEW ENGLAND JOURL OF MEDICINE | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma | 2013 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Targeted Therapy in Relapsed Classical Hodgkin Lymphoma | 2013 |
Other Publication | Blood | Plasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma | 2013 |
Other Publication | NEW ENGLAND JOURL OF MEDICINE | Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma | 2013 |
Other Publication | ANLS OF ONCOLOGY | Efficacy of abbreviated Stanford V chemotherapy | 2013 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | The efficacy and tolerability of adriamycin, bleomycin | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Bruton Tyrosine Kise Inhibitor Ibrutinib | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin | 2012 |
Other Publication | ONCOLOGIST | Brentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma | 2012 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Brentuximab Vedotin | 2012 |
Other Publication | LEUKEMIA & LYMPHOMA | Cardiac toxicity associated with bevacizumab | 2012 |
Other Publication | INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS | 2011 |
Other Publication | CLINICAL CANCER RESEARCH | MicroRs Are Independent Predictors of Outcome in Diffuse Large B | 2011 |
Other Publication | LEUKEMIA & LYMPHOMA | Current concepts and controversies in the magement of early stage Hodgkin lymphoma | 2011 |
Other Publication | Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. | Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B | 2010 |
Other Publication | EXPERT REVIEW OF ANTICANCER THERAPY | Risk stratification in extranodal tural killer/T-cell lymphoma | 2010 |
Other Publication | LANCET ONCOLOGY | Magement of T-cell and tural-killer-cell neoplasms in Asia | 2009 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Phase I Study of the Humanized Anti | 2009 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Impact of positive positron emission tomography | 2007 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy | 2004 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era | 2014 |
Other Publication | LEUKEMIA & LYMPHOMA | A multicenter phase II trial to determine the safety | 2013 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines | 2013 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphomas, version 1.2013. | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Gene Expression-Based Model Using Formalin-Fixed Paraffin | 2013 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's Lymphomas, version 3.2012. | 2012 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines | 2012 |
Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines | 2012 |
Other Publication | BLOOD | In situ vaccition against mycosis fungoides by intratumoral injection of a TLR9 | 2012 |
Other Publication | INVESTIGATIOL NEW DRUGS | Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies | 2011 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin lymphoma. | 2011 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma | 2011 |
Other Publication | OBSTETRICS AND GYNECOLOGY | Lymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus | 2011 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2011 |
Other Publication | JOURL OF THE AMERICAN COLLEGE OF RADIOLOGY | ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II | 2011 |
Other Publication | SCIENCE TRANSLATIOL MEDICINE | CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma | 2011 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study | 2010 |
Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2010 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. | 2010 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | Lymphoma cell VEGFR2 expression detected | 2010 |
Other Publication | CURRENT OPINION IN ONCOLOGY | The emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma | 2009 |
Other Publication | ARCHIVES OF DERMATOLOGY | Prognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma | 2009 |
Other Publication | LEUKEMIA & LYMPHOMA | Extranodal tural killer/T-cell lymphoma: current concepts in biology and treatment | 2009 |
Other Publication | ONCOLOGY RESEARCH | Dymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr | 2009 |
Other Publication | JOURL OF THE AMERICAN ACADEMY OF DERMATOLOGY | Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab | 2008 |
Other Publication | Clinical advances in hematology & oncology : H&O | Evaluation and magement of angioimmunoblastic T-cell lymphoma | 2008 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin disease/lymphoma. | 2008 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. | 2008 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphomas. | 2008 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. | 2006 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. | 2006 |
Other Publication | Jourl of the tiol Comprehensive Cancer Network | Magement of advanced stage Hodgkin lymphoma. | 2006 |
Other Publication | ANLS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
Other Publication | INVESTIGATIOL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
Other Publication | Investigatiol New Drugs, | A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003) | 2005 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane alog | 2003 |
Other Publication | Blood | Treatment of refractory | 1999 |
Other Publication | Leukemia & lymphoma | Bevacizumab and cyclosphosphamide, doxorubicin | 2014 |
Other Publication | Journal of clinical oncology | Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte | 2014 |
Other Publication | Blood | Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma | 2014 |
Other Publication | Blood | Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades | 2013 |
Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma | 2013 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Targeted Therapy in Relapsed Classical Hodgkin Lymphoma | 2013 |
Other Publication | Blood | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma | 2013 |
Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | 2013 |
Other Publication | ANNALS OF ONCOLOGY | Efficacy of abbreviated Stanford V chemotherapy | 2013 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | The efficacy and tolerability of adriamycin, bleomycin | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma | 2013 |
Other Publication | BLOOD | Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Bruton Tyrosine Kinase Inhibitor Ibrutinib | 2013 |
Other Publication | BLOOD | Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma | 2012 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin | 2012 |
Other Publication | ONCOLOGIST | Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma | 2012 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Brentuximab Vedotin | 2012 |
Other Publication | LEUKEMIA & LYMPHOMA | Cardiac toxicity associated with bevacizumab | 2012 |
Other Publication | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS | 2011 |
Other Publication | CLINICAL CANCER RESEARCH | MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B | 2011 |
Other Publication | LEUKEMIA & LYMPHOMA | Current concepts and controversies in the management of early stage Hodgkin lymphoma | 2011 |
Other Publication | Hematology / the Education Program of the American Society of Hematolo | Optimal therapy of advanced Hodgkin lymphoma. | 2011 |
Other Publication | Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. | Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B | 2010 |
Other Publication | EXPERT REVIEW OF ANTICANCER THERAPY | Risk stratification in extranodal natural killer/T-cell lymphoma | 2010 |
Other Publication | Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, | Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes | 2009 |
Other Publication | LANCET ONCOLOGY | Management of T-cell and natural-killer-cell neoplasms in Asia | 2009 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Phase I Study of the Humanized Anti | 2009 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Impact of positive positron emission tomography on prediction of freedom from progression after | 2007 |
Other Publication | LEUKEMIA & LYMPHOMA | Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine | 2007 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy | 2004 |
Other Publication | Pediatric blood & cancer | ACR appropriateness Criteria® pediatric Hodgkin lymphoma. | 2014 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era | 2014 |
Other Publication | ONCOLOGY-NEW YORK | ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma | 2013 |
Other Publication | LEUKEMIA & LYMPHOMA | A multicenter phase II trial to determine the safety | 2013 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines | 2013 |
Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphomas, version 1.2013. | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Gene Expression-Based Model Using Formalin | 2013 |
Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's Lymphomas, version 3.2012. | 2012 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines | 2012 |
Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines | 2012 |
Other Publication | RADIATION ONCOLOGY | Interim-treatment quantitative PET parameters predict progression | 2012 |
Other Publication | BLOOD | In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 | 2012 |
Other Publication | CLINICAL CANCER RESEARCH | A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed | 2012 |
Other Publication | INVESTIGATIONAL NEW DRUGS | Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine | 2011 |
Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin lymphoma. | 2011 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma | 2011 |
Other Publication | BLOOD | Prediction of survival in diffuse large B | 2011 |
Other Publication | OBSTETRICS AND GYNECOLOGY | Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus | 2011 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2011 |
Other Publication | JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY | ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II | 2011 |
Other Publication | SCIENCE TRANSLATIONAL MEDICINE | CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma | 2011 |
Other Publication | Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, | Prediction of Survival In Diffuse Large B | 2010 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study | 2010 |
Other Publication | CURRENT PROBLEMS IN CANCER | ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma | 2010 |
Other Publication | CLINICAL CANCER RESEARCH | Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed | 2010 |
Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2010 |
Other Publication | Journal of the National Comprehensive Cancer Network | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. | 2010 |
Other Publication | BLOOD | Interim positron emission tomography scans in diffuse large B-cell lymphoma | 2010 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival | 2010 |
Other Publication | CURRENT OPINION IN ONCOLOGY | The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma | 2009 |
Other Publication | ARCHIVES OF DERMATOLOGY | Prognostic Factors in Primary Cutaneous Anapl | 2009 |
Other Publication | Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., | Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR) | |
Other Publication | CLINICAL LYMPHOMA & MYELOMA | Targeting CD40 in Waldenstrom's Macroglobulinemia | 2009 |
Other Publication | LEUKEMIA & LYMPHOMA | Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment | 2009 |
Other Publication | ONCOLOGY RESEARCH | Dynamic CD8 T-Cell Responses to Tumor | 2009 |
Other Publication | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab | 2008 |
Other Publication | Clinical advances in hematology & oncology : H&O | Evaluation and management of angioimmunoblastic T-cell lymphoma | 2008 |
Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin disease/lymphoma. | 2008 |
Other Publication | BLOOD | Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with | 2008 |
Other Publication | Journal of the National Comprehensive Cancer Network | Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. | 2008 |
Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphomas. | 2008 |
Other Publication | CANCER | Non-Hodgkin lymphoma of the breast | 2007 |
Other Publication | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | Treatment of mantle cell lymphoma: Current approach and future directions | 2006 |
Other Publication | ARCHIVES OF DERMATOLOGY | Staging accuracy in mycosis fungoides | 2006 |
Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. | 2006 |
Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. | 2006 |
Other Publication | Journal of the National Comprehensive Cancer Network | Management of advanced stage Hodgkin lymphoma. | 2006 |
Other Publication | ANNALS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
Other Publication | INVESTIGATIONAL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
Other Publication | Investigational New Drugs, | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane analog | 2003 |
Other Publication | Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litc | A phase I trial of doxorubicin, paclitaxel | 2001 |
Other Publication | Blood | Treatment of refractory | 1999 |
Ranjana Advani, Other has not yet indicated the hospitals that she is affiliated with.
Years In Practice: 36 (started in 1989)
Accepts New Patients: Yes
Ranjana Advani, Other has not yet listed the medications that she commonly prescribes.
Ranjana Advani, Other has not yet added any information about her practice's billing policies and payment options.